TRIM24-RIP3 axis perturbation accelerates osteoarthritis pathogenesis
Objectives
Recently, necroptosis has attracted increasing attention in arthritis research; however, it remains unclear whether its regulation is involved in osteoarthritis (OA) pathogenesis. Since receptor-interacting protein kinase-3 (RIP3) plays a pivotal role in necroptosis and its dysregulation is involved in various pathological processes, we investigated the role of the RIP3 axis in OA pathogenesis.
Methods
Experimental OA was induced in wild-type or Rip3 knockout mice by surgery to destabilise the medial meniscus (DMM) or the intra-articular injection of adenovirus carrying a target gene (Ad-Rip3 and Ad-Trim24 shRNA). RIP3 expression was examined in OA cartilage from human patients; Trim24, a negative regulator of RIP3, was identified by microarray and in silico analysis. Connectivity map (CMap) and in silico binding approaches were used to identify RIP3 inhibitors and to examine their direct regulation of RIP3 activation in OA pathogenesis.
Results
RIP3 expression was markedly higher in damaged cartilage from patients with OA than in undamaged cartilage. In the mouse model, adenoviral RIP3 overexpression accelerated cartilage disruption, whereas Rip3 depletion reduced DMM-induced OA pathogenesis. Additionally, TRIM24 knockdown upregulated RIP3 expression; its downregulation promoted OA pathogenesis in knee joint tissues. The CMap approach and in silico binding assay identified AZ-628 as a potent RIP3 inhibitor and demonstrated that it abolished RIP3-mediated OA pathogenesis by inhibiting RIP3 kinase activity.
Conclusions
TRIM24-RIP3 axis perturbation promotes OA chronicity by activating RIP3 kinase, suggesting that the therapeutic manipulation of this pathway could provide new avenues for treating OA.
Топ-30
Журналы
|
1
2
3
4
|
|
|
International Journal of Molecular Sciences
4 публикации, 5.33%
|
|
|
International Immunopharmacology
4 публикации, 5.33%
|
|
|
Frontiers in Cell and Developmental Biology
3 публикации, 4%
|
|
|
Frontiers in Pharmacology
3 публикации, 4%
|
|
|
Biomedicine and Pharmacotherapy
3 публикации, 4%
|
|
|
Biomaterials
3 публикации, 4%
|
|
|
Frontiers in Immunology
2 публикации, 2.67%
|
|
|
Scientific Reports
2 публикации, 2.67%
|
|
|
EBioMedicine
2 публикации, 2.67%
|
|
|
PLoS ONE
2 публикации, 2.67%
|
|
|
FASEB Journal
2 публикации, 2.67%
|
|
|
Advanced Science
2 публикации, 2.67%
|
|
|
Journal of Immunology Research
2 публикации, 2.67%
|
|
|
Journal of Ethnopharmacology
2 публикации, 2.67%
|
|
|
Bone Research
1 публикация, 1.33%
|
|
|
Pharmaceuticals
1 публикация, 1.33%
|
|
|
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
1 публикация, 1.33%
|
|
|
Cells
1 публикация, 1.33%
|
|
|
Molecular Neurobiology
1 публикация, 1.33%
|
|
|
Experimental and Molecular Medicine
1 публикация, 1.33%
|
|
|
Food and Chemical Toxicology
1 публикация, 1.33%
|
|
|
Bioorganic Chemistry
1 публикация, 1.33%
|
|
|
Biochemical Pharmacology
1 публикация, 1.33%
|
|
|
Journal of Advanced Research
1 публикация, 1.33%
|
|
|
Orthopaedic surgery
1 публикация, 1.33%
|
|
|
Immunology Letters
1 публикация, 1.33%
|
|
|
MedComm
1 публикация, 1.33%
|
|
|
Journal of Bone and Mineral Research
1 публикация, 1.33%
|
|
|
Small
1 публикация, 1.33%
|
|
|
Bioengineered
1 публикация, 1.33%
|
|
|
1
2
3
4
|
Издатели
|
5
10
15
20
25
30
|
|
|
Elsevier
27 публикаций, 36%
|
|
|
Springer Nature
10 публикаций, 13.33%
|
|
|
Wiley
10 публикаций, 13.33%
|
|
|
Frontiers Media S.A.
8 публикаций, 10.67%
|
|
|
MDPI
7 публикаций, 9.33%
|
|
|
Taylor & Francis
3 публикации, 4%
|
|
|
Public Library of Science (PLoS)
2 публикации, 2.67%
|
|
|
Hindawi Limited
2 публикации, 2.67%
|
|
|
Oxford University Press
2 публикации, 2.67%
|
|
|
Zhejiang Daxue
1 публикация, 1.33%
|
|
|
Federation of American Societies for Experimental Biology (FASEB)
1 публикация, 1.33%
|
|
|
Scientific Scholar
1 публикация, 1.33%
|
|
|
5
10
15
20
25
30
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.